Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery

• Status: Recruiting
• Trial end date: 2028-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Along with aging population, cancer incidence and mortality are increasing. However, despite advances in oncology and surgery, long-term survival of cancer patients is far from optimal. Dexmedetomidine is a highly selective alpha 2 adrenergic receptor agonist with sedative, analgesic, and anxiolytic effects. Studies showed that perioperative use of dexmedetomidine reduces delirium and some non-delirium complications after surgery. In long-term follow-up studies of older patients who, for other reasons, were randomized to receive either dexmedetomidine or placebo during intra- or postoperative period, dexmedetomidine use was associated with improved long-term survival. This multicenter randomized trial aims to investigate the effect of perioperative dexmedetomidine on long-term outcomes in older patients undergoing cancer surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Collaborator: Peking University
• Treatments: Dexmedetomidine

Criteria

Inclusion criteria:

1. Aged 60 years or older.

2. Scheduled to undergo radical surgery for cancer under general anesthesia, with an expected surgical duration of 2 hours or longer.

3. Required patient-controlled intravenous analgesia after surgery.

Exclusion criteria:

1. Inability to communicate preoperatively due to visual, auditory, verbal. or other reasons.

2. Surgery for breast cancer or intracranial tumor.

3. Preoperative severe sinus bradycardia (<50 beats per minute), sick sinus syndrome，or second-degree or above atrioventricular block without pacemaker.

4. Severe hepatic dysfunction (Child-Pugh class C).

5. Severe renal dysfunction (requirement of renal replacement therapy before surgery).

6. Enrolled in other clinical studies.